ACAD
Acadia Pharmaceuticals Inc
Halal Rating :
Last Price
$17.57
Last updated:
Market Cap
-
7D Change
-1.84%
1 Year Change
-36.71%
Company Overview
Industries
Exchange
Next Earnings Date
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders. Their primary product is NUPLAZID® (pimavanserin), which was the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops treatments for Rett syndrome and other neurological conditions.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $250.4m | $218.76m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $241.96m | $211.53m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $205.83m | $190.62m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Acadia Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.